FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107949967> ?p ?o ?g. }

• W2107949967 endingPage "908" @default.
• W2107949967 startingPage "900" @default.
• W2107949967 abstract "Objective: The current study examined the efficacy and safety of rasagiline, a selective MAO-B inhibitor, for the treatment of persistent negative symptoms. Methods: Sixty people with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, schizophrenia or schizoaffective disorder, who met a priori criteria for persistent negative symptoms, were randomized to receive rasagiline, 1mg/d ( n = 31) or placebo ( n = 29) in a 12-week, double-blind, placebo-controlled clinical trial. The Scale for the Assessment of Negative Symptoms (SANS) total score was used to assess change in negative symptoms. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), N-Back test, a probabilistic learning task, and a delayed discounting task were used to assess cognition. Results: In a mixed model analysis of covariance (MM-ANCOVA), with time as a continuous variable, there was a significant treatment × time effect for SANS total score ( F = 5.61( df = 1,40.3), P = .023). The treatment × time interaction effect was also significant for the SANS avolition subscale score ( F (1,40.2) = 10.41, P = .002). In a post hoc MM-ANCOVA analyses, with time as a categorical variable, group differences were significant at week 12 for SANS total score ( t (37.3) = 2.15; P = .04; d = −0.41) and SANS avolition subscale score ( t (49.0) = 3.06; P = .004; d = −0.46). There was a significant difference in number of participants with a ≥20% reduction in SANS avolition score (χ 2 (1) = 10.94; P = .0009), but not in SANS total score (χ 2 (1) = 1.11; P = .29). There were no significant group differences on the RBANS, N-Back, probabilistic learning, or delayed discounting tasks. Conclusions: Study results support future studies of the utility of rasagiline for the treatment of negative symptoms, including avolition (clinicaltrials.gov trial number: NCT00492336)." @default.
• W2107949967 created "2016-06-24" @default.
• W2107949967 creator A5007947327 @default.
• W2107949967 creator A5028131133 @default.
• W2107949967 creator A5045314404 @default.
• W2107949967 creator A5046858731 @default.
• W2107949967 creator A5070223359 @default.
• W2107949967 creator A5070713968 @default.
• W2107949967 creator A5075445771 @default.
• W2107949967 creator A5077670489 @default.
• W2107949967 date "2014-11-02" @default.
• W2107949967 modified "2023-09-27" @default.
• W2107949967 title "Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia" @default.
• W2107949967 cites W1616286551 @default.
• W2107949967 cites W1977138162 @default.
• W2107949967 cites W1977924236 @default.
• W2107949967 cites W1991367158 @default.
• W2107949967 cites W1995410280 @default.
• W2107949967 cites W1997116028 @default.
• W2107949967 cites W1998152406 @default.
• W2107949967 cites W1999689270 @default.
• W2107949967 cites W2009969771 @default.
• W2107949967 cites W2019350197 @default.
• W2107949967 cites W2020847388 @default.
• W2107949967 cites W2043941998 @default.
• W2107949967 cites W2047892425 @default.
• W2107949967 cites W2054067072 @default.
• W2107949967 cites W2073455958 @default.
• W2107949967 cites W2079767332 @default.
• W2107949967 cites W2082483237 @default.
• W2107949967 cites W2082953267 @default.
• W2107949967 cites W2106131368 @default.
• W2107949967 cites W2107329846 @default.
• W2107949967 cites W2109059823 @default.
• W2107949967 cites W2111085230 @default.
• W2107949967 cites W2115253307 @default.
• W2107949967 cites W2118423385 @default.
• W2107949967 cites W2120935254 @default.
• W2107949967 cites W2123236884 @default.
• W2107949967 cites W2129116806 @default.
• W2107949967 cites W2152853034 @default.
• W2107949967 cites W2156436903 @default.
• W2107949967 cites W2159006998 @default.
• W2107949967 cites W2161632903 @default.
• W2107949967 cites W2165379748 @default.
• W2107949967 cites W2170792659 @default.
• W2107949967 cites W2171111401 @default.
• W2107949967 cites W2302113434 @default.
• W2107949967 cites W2316134431 @default.
• W2107949967 cites W2595176684 @default.
• W2107949967 cites W4234210156 @default.
• W2107949967 cites W4251508433 @default.
• W2107949967 cites W4255381530 @default.
• W2107949967 doi "https://doi.org/10.1093/schbul/sbu151" @default.
• W2107949967 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4466175" @default.
• W2107949967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25368372" @default.
• W2107949967 hasPublicationYear "2014" @default.
• W2107949967 type Work @default.
• W2107949967 sameAs 2107949967 @default.
• W2107949967 citedByCount "16" @default.
• W2107949967 countsByYear W21079499672015 @default.
• W2107949967 countsByYear W21079499672016 @default.
• W2107949967 countsByYear W21079499672017 @default.
• W2107949967 countsByYear W21079499672018 @default.
• W2107949967 countsByYear W21079499672020 @default.
• W2107949967 countsByYear W21079499672021 @default.
• W2107949967 countsByYear W21079499672022 @default.
• W2107949967 countsByYear W21079499672023 @default.
• W2107949967 crossrefType "journal-article" @default.
• W2107949967 hasAuthorship W2107949967A5007947327 @default.
• W2107949967 hasAuthorship W2107949967A5028131133 @default.
• W2107949967 hasAuthorship W2107949967A5045314404 @default.
• W2107949967 hasAuthorship W2107949967A5046858731 @default.
• W2107949967 hasAuthorship W2107949967A5070223359 @default.
• W2107949967 hasAuthorship W2107949967A5070713968 @default.
• W2107949967 hasAuthorship W2107949967A5075445771 @default.
• W2107949967 hasAuthorship W2107949967A5077670489 @default.
• W2107949967 hasBestOaLocation W21079499671 @default.
• W2107949967 hasConcept C118552586 @default.
• W2107949967 hasConcept C126322002 @default.
• W2107949967 hasConcept C14216870 @default.
• W2107949967 hasConcept C142724271 @default.
• W2107949967 hasConcept C15744967 @default.
• W2107949967 hasConcept C169900460 @default.
• W2107949967 hasConcept C204787440 @default.
• W2107949967 hasConcept C27081682 @default.
• W2107949967 hasConcept C2776412080 @default.
• W2107949967 hasConcept C2776464990 @default.
• W2107949967 hasConcept C2779727114 @default.
• W2107949967 hasConcept C2780325297 @default.
• W2107949967 hasConcept C2780442968 @default.
• W2107949967 hasConcept C3019023267 @default.
• W2107949967 hasConcept C67761136 @default.
• W2107949967 hasConcept C70410870 @default.
• W2107949967 hasConcept C71924100 @default.
• W2107949967 hasConceptScore W2107949967C118552586 @default.
• W2107949967 hasConceptScore W2107949967C126322002 @default.
• W2107949967 hasConceptScore W2107949967C14216870 @default.

• next